Dallas’ Mark Cuban Cost Plus Drug Company announced a collaboration today with Houston-based OncoPower that will enable cancer patients using OncoPower to look up pricing and order less expensive medications.
The companies say they’ll build on OncoPower’s support for cancer patients by launching a Medication Savings Suite which will leverage Cost Plus Drugs’ competitive pricing on generic medication.
The new suite integrates with OncoPower’s Pill Reminder to improve treatment adherence, provide cost transparency, and engage patients at home, the companies say.
OncoPower is a free app and website with ‘social media style format’
MCCPDC’s new partner was launched by Houston-based Witty Health to help patients manage complexities found in cancer care, including identifying clinical trials they might be able to participate in. OncoPower offers a free app and website with a social media-style format where patients and providers can support one another. Patients can use it to access professionals including dietitians and behavioral therapists, as well as cancer education and meditation content, tools for treatment adherence, and clinical trial mapping.
“We’re excited to work with OncoPower to bring lower prescription drug prices to consumers,” Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company, said in a statement. “Cost Plus Drugs and OncoPower share a common goal of providing consumers the lowest possible price for their prescription medication. With Cost Plus Drugs, consumers can be confident they are getting a fair price and the convenience of medication mailed directly to their homes.”
Like OncoPower, Mark Cuban’s startup has targeted consumers directly since it launched its online pharmacy in January 2022, and both companies say they aim to promote cost transparency and affordable access to medications.
“Cancer patients are often left to navigate a very complex and disparate healthcare world largely on their own,” Whitney Isola, co-founder and COO of Witty Health, said in the statement. “Bringing care tools and high-quality clinical trial information to patients in one supportive care space is at the heart of what we do. Working with companies like Cost Plus Drugs gives us the ability to deliver a world-class product with information on treatment options and medications at prices that patients can afford.”
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.
R E A D N E X T
-
Mark Cuban has some hot takes on the metaverse, and he doesn't stop there. He made a recent virtual appearance on the YouTube channel Altcoin Daily to share his thoughts on Bitcoin, Ethereum, XRP, Cardano, cryptocurrency in general, and more.
-
Whether he's buying a pro pickleball team or disrupting big pharma with his cost-plus drug company, Mark Cuban says he's a "ready, fire, aim" businessman. So he surrounds himself with "ready, aim, fire" perfectionists to keep him from "screwing everything up." That's just one insight the billionaire shared in a fireside chat with Backstage Capital founder Arlan Hamilton at the Venture Dallas conference last week. “There's always going to be somebody smarter, there's always going to be somebody faster, better," Cuban added. "I just try to work a little harder.”
-
In January, the Mark Cuban Cost Plus Drug Company launched its online pharmacy directly to consumers, aiming to "bypass middlemen and outrageous markups." In October, it partnered with its first U.S. health plan, Capital Blue Cross. Now, by partnering with EmsanaRx, MCCPDC has made its first move into the self-insured employer drug market. Mark Cuban says EmsanaRx's "technological capabilities to customize to the needs of self-funded employers" will help his startup "bring lower cost medicines to a wider swath of the American public."
-
The Cancer Prevention & Research Institute of Texas has provided more than $3.1 billion in funding toward the development of cancer-fighting therapeutics, devices, diagnostics, and tools since 2010. It's now issued a call for startups and early-stage companies to apply for product development research grants for the 2023 fiscal year. “CPRIT’s mission is to invest in the research prowess of Texas institutions while expediting breakthroughs in cancer cures and prevention,” CEO Wayne Roberts said last May.
-
The early-stage startup's QmTRIAGE software platform uses AI and machine learning to detect early breast cancers with a "high rate" of accuracy, MedCognetics says. The company has worked with UT Southwestern and UT Dallas to ensure its AI improves outcomes for "all ethnicities," at a time when racial disparities in AI have become a growing concern.
